论文信息 - Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. - 字舞流文

Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

E. Jonasch | N. Rashid | L. Voorwerk | A. Heimberger | J. T. Chang | M. Khasraw | P. Pilié | M. Slagter | R. Ferrarotto | M. Kok | S-Y Lin | D. J. McGrail | N. Ueno